Novo Nordisk A/S had a pretty good 2023, its full-year sales increasing by 36% at constant exchange rates and its operating profit by 44% – both above analysts’ expectations. It achieved its goal of securing more than a third of the entire global diabetes market, and thanks to the relaunch of Wegovy (semaglutide injection) a year or so ago, saw its obesity sales jump by 154% globally and nearly 400% in the US.
Novo Nordisk Has Its Best Year Ever
The Danish group has seen the kind of profit growth that other companies can only dream of. But nothing lasts forever: its 2024 guidance looks rather more modest.
More from Earnings
More from Business
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
Stock prices plummeted, particularly for vaccine makers and cell and gene therapy developers, after the US FDA’s top biologics overseer resigned over vaccine misinformation concerns.